drugset
drugset / Trial / NCT03900325

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

NCT03900325 ↗

Phase 2 Unknown 6 enrolled Bird Rock Bio, Inc.
Non-randomizedSequentialSingle-blindTreatment

Summary

This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.

Timeline

Start
2019-08-01
Primary completion
2020-01
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimacimab Monoclonal antibody 2.5 mg/kg —

Indications

gastroparesis